Skip to content
DataLookout
Menu

NCT07636811

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 10 words
    • Trial sites expanded: 10 → 20 locations
  2. Notable Eligibility criteria expanded, about 11 words
    • Trial sites expanded: 3 → 10 locations
    • Study completion date: Jul 23, 2031 to Jul 30, 2031
  3. Minor Study sites: 2 to 3
    • Start date changed from estimate of Aug 31, 2026 to Aug 17, 2026
    v4
  4. Notable Recruitment opened
    • Start date: Jul 31, 2026 to Aug 31, 2026
    • Site details revised at 2 of 2 sites
    v3
  5. Notable Start date: Jul 1, 2026 to Jul 31, 2026v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Double-Blind Period: Change from baseline in brain amyloid burden measured in centiloids (CLs)
Timeframe: Up to 24 months

Secondary (5)

Double-Blind Period: Change from baseline in APP protein concentration in cerebrospinal fluid (CSF)
Double-Blind Period: Change from baseline in the concentration of amyloid beta proteins in CSF
Double-Blind Period: Change from baseline in the concentration of tau proteins in plasma
Double-Blind Period: Change from baseline on a cognitive scale
Double-blind Period and Open-label Extension (OLE) Period: Frequency of adverse events (AEs)

Arms and interventions

Mivelsiran (Treatment Group A)Experimental

Participants will be administered multiple low doses of mivelsiran.

Mivelsiran (Treatment Group B)Experimental

Participants will be administered multiple high doses of mivelsiran.

Placebo (Treatment Group C)Placebo comparator

Participants will be administered multiple doses of placebo.

Drugs: Mivelsiran, Placebo

Sites

20 sites in 3 countries

United States 13, Spain 6, United Kingdom 1